Welcome to visit the Wang Lab!
Our research employs molecular, cellular, and genetic approaches to investigate signaling mechanisms controlling cancer progression, metastasis, metabolic, and immunological programming. The laboratory is interested in translational studies for human diseases including cancer and obesity.
This website is still under construction and welcome back from time to time for updates (August 9, 2017).
Areas of research interests
My laboratory is interested in signaling transduction mechanisms which play determinant roles in cellular deregulation, including cancer and obesity using biochemical, molecular, cellular, and genetic approaches. The ultimate goal is to take our discoveries to translational arena with real-life impact. This is a long journey. We are open-arm to young scientists who enjoy the pleasure of cracking mysteries through bench experiments in a creative and collaborative environment.
- Targeting advanced breast cancer refractory to conventional targeted therapies: This study focuses on the following two groups of breast cancer: (1) the estrogen receptor a (ERa)-positive breast cancer resistant to endocrine therapy, in particular those progressed on the common frontline anti-estrogen tamoxifen and developed resistance to fulvestrant, currently the only clinically approved pure anti-estrogen as the second- or third-line treatment; and (2) the triple-negative breast cancer (TNBC), which lacks the expression of ErbB-2, ERa, and PgR (progesterone receptor), and is therefore refractory to almost all of the traditional targeted therapy. These cancer types, for which therapeutic options are limited, represent the current major challenges in clinical management of breast cancer. Our research aims to further understand the underlying mechanisms of the malignant phenotypes and to develop efficient approaches for treatment.
- Mapping the interface of proliferation and cancer progression, metastasis, and response to genotoxic as well as targeted therapies: It is widely accepted as a central dogma that it is tumor metastasis that is responsible for most cancer-caused lethality. However, it is equally important to note that deregulated proliferation at the metastatic sites renders the fatality of the disseminated tumors. Research in our group has pin-pointed the proliferating cell nuclear antigen (PCNA) as a key regulator, not only in cancer cell proliferation, but also in metastasis and the crosstalk between the cancer epithelium and the stromal compartment.
- Reprogramming tumor stromal landscape to modulate immune response of malignant cancer: Characterization of downstream effectors of growth factor signaling pathways has led us to the identification of potential enzymes which is capable of modifying cell surface context of proteoglycans. Intensive work is ongoing to determine how the extracellular activity modulate sensitivity of cancer cells and its stromal components to immune surveillance.
- Deciphering the interface of proliferation and differentiation as a mechanism underlying diet-induced obesity: Besides cancer biology, we have identified novel function of PCNA in controlling the fate of adipose tissue development. We found that PCNA is able to regulate adipocyte differentiation and function through a site-specific phosphorylation of PCNA. Current work is developing small molecule inhibitors of the phosphorylation machinery as a means of intervention to diet-induced obesity.
Center for Molecular Medicine, China Medical University Hospital
Graduate Institute of Biomedical Sciences, China Medical University (http://www.cmu.edu.tw/)
9F Cancer Center Building, No. 6, Hsueh-Shih Road, Taichung, Taiwan 404, R.O.C.
中國醫藥大學 生物醫學研究所 (http://www.cmu.edu.tw/)